Xenon Pharmaceuticals Inc. $XENE Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 63.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,470 shares of the biopharmaceutical company’s stock after selling 152,568 shares during the period. Granahan Investment Management LLC’s holdings in Xenon Pharmaceuticals were worth $3,512,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XENE. Holocene Advisors LP acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $56,637,000. Wellington Management Group LLP grew its position in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after buying an additional 1,435,096 shares during the last quarter. Geode Capital Management LLC raised its stake in Xenon Pharmaceuticals by 1,294.2% during the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock worth $30,369,000 after acquiring an additional 900,746 shares in the last quarter. Braidwell LP raised its stake in Xenon Pharmaceuticals by 33.0% during the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after acquiring an additional 895,154 shares in the last quarter. Finally, Commodore Capital LP lifted its position in Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after acquiring an additional 700,000 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insiders Place Their Bets

In other news, insider Andrea Difabio sold 1,342 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $74,118.66. Following the completion of the sale, the insider owned 7,301 shares in the company, valued at $403,234.23. This represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher John Kenney sold 1,410 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the sale, the insider directly owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This represents a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 336,707 shares of company stock valued at $19,622,565. 4.07% of the stock is owned by company insiders.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $54.66 on Tuesday. The firm’s fifty day moving average is $43.97 and its two-hundred day moving average is $42.07. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95. The firm has a market cap of $4.55 billion, a PE ratio of -12.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the firm earned ($0.84) earnings per share. Research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on XENE. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Morgan Stanley set a $97.00 target price on Xenon Pharmaceuticals in a report on Monday, March 9th. Needham & Company LLC upped their target price on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $71.88.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.